Article Sidebar
Published:
Jul 11, 2026Keywords:
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Impact of using metformin alone or with sitagliptin on diabetes management and their association with cardiovascular and renal outcomes
Abstract
Purpose: To investigate the effect of metformin monotherapy against sitagliptin-metformin combination on blood pressure, glucose metabolism, renal function, and lipid profile.
Methods: Three separate groups of 150 participants each were assigned at random and equally. Group 1 served as the control. Group 2 received metformin, then group 3 received sitagliptin with metformin. Biochemical and physiological parameters, including HbA1c, fasting blood sugar (FBS), blood pressure, high-sensitivity cardiac troponin (hs-cTn), lipid profile, blood urea (BU), and serum creatinine (Cr), were measured and recorded.
Results: Groups 1 and 2 showed significantly higher HbA1c and FBS related to control group (p < 0.05), although group 2 had higher FBS levels. Group 2 had significantly higher systolic blood pressure and high-sensitivity cardiac troponin (hs-cTn) in comparison to control (p < 0.05), whereas group 2 demonstrated lower high-sensitivity cardiac troponin (hs-cTn) and systolic pressure values. Despite total cholesterol was relatively higher in group 1, the lipid profile assessment revealed just modest, non-significant variations. In both groups 1 and 2, renal function parameters exhibited considerably diminished BU and Cr, suggesting possible nephroprotective effects.
Conclusion: In comparison to metformin alone, a combination of sitagliptin and metformin optimises the regulation of cardiovascular and renal indicators.
